Publication: 2249

Publication: 2249

Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Cancer Res vol 76 (13) 3702-3710

Year:: 2016
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Meta-Analysis
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:: 951 is parent abstract. This work was supported, in part, by the Dana Foundation; Susan G. Komen for the Cure Foundation Grant KG101016; The 26.2 with Donna Foundation (EAP); and The National Institutes of Health, National Cancer Institute Grants R01-CA152045.

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:: 5

Parents:: 951 962 2260
Children:: None

Program:: OGC
Primary Committee:: Breast
Sec. Committees:

Pharmas:
Grants:: UG1CA189823, U10CA180821 , R01 CA152045, U10 CA025224, U10 CA180821

Corr. Author:
Authors:: Keith L. Knutson Raphael Clynes Barath Shreeder Patrick Yeramian Kathleen P. Kemp Karla Ballman Kathleen S. Tenner Courtney L. Erskine Nadine Norton Donald Northfelt Winston Tan Carmen Calfa Mark Pegram Elizabeth A. Mittendorf Edith A. Perez

Networks:: FL028, LAPS-MA036, LAPS-MN026, PR028

Study
Multiple Studies, or Legacy Studies in Alliance Study:: NCCTG-N0337, NCCTG-N98-32-52, NCCTG-N0938
Phases:: 2, N/A

Keywords:: Herceptin, immune response, breast cancer, monoclonal antibodies, vaccine, biomarker, diagnostic, antibody, T cell, survival